Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Hong-Anh T Tu"'
Publikováno v:
Vaccine, 31(32), 3300-3307. ELSEVIER SCI LTD
Objective: This study aims to assess the cost-effectiveness of rotavirus immunization in Indonesia, taking breastfeeding patterns explicitly into account.Method: An age-structured cohort model was developed for the 2011 Indonesia birth cohort. Next,
Autor:
Maarten J. Postma, Herman J. Woerdenbag, Hong Anh T. Tu, Robin de Vries, Shu-Chuen Li, Marinus van Hulst, Hoa H. Le
Publikováno v:
Value in Health Regional Issues, 1(1), 7-14. HANLEY & BELFUS-ELSEVIER INC
Objectives: To perform acost-effectiveness analysis and to identify the coseffectiveness affordability levels for a newborn universal vaccination program against hepatitis B virus (HBV) in Vietnam. Methods: By using a Markov model, we simulated a Vie
Publikováno v:
Expert review of vaccines, 11(3), 303-317. TAYLOR & FRANCIS LTD
The BCG vaccine was introduced in 1921 and remains the only licensed vaccine for the prevention of TB worldwide. Despite its extensive use, the BCG vaccine lacks the ability to fully control the TB-endemic and -pandemic situations. The BCG vaccine is
Autor:
Maarten J. Postma, Lolkje T. W. de Jong-van den Berg, Jens H. J. Bos, Herman J. Woerdenbag, Sander van Assen, Hong Anh T. Tu, Sipke T. Visser, Jan Wilschut
Publikováno v:
Clinical Therapeutics, 32(1), 133-144. Elsevier
Objectives: The main aims of this work were to describe patterns of medication use in the treatment of chronic hepatitis B virus (HBV) infection in patients in the northern part of the Netherlands and to compare these practices with established guide
Autor:
Herman J. Woerdenbag, Maarten J. Postma, Marinus van Hulst, Hong-Anh T Tu, Sumit Kane, Arthorn Riewpaiboon
Publikováno v:
Expert Review of Vaccines. 8:907-920
Economic evaluations, in particular cost-effectiveness, are important determinants for policy makers and stakeholders involved in decision-making for health interventions. Up until now, most evaluations of cost-effectiveness of hepatitis B vaccinatio
Autor:
Vica Dang, Hong Anh T. Tu, Shaun K. Morris, Beate Sander, Natasha S. Crowcroft, Ripudaman S. Minhas, Shelley L. Deeks, Lisa Strifler, Frances B. Jamieson
Publikováno v:
Journal of the Pediatric Infectious Diseases Society. 5(4)
Of key points Although relatively rare, invasive meningococcal disease continues to be a health concern, especially in young children. This systematic review clearly delineates both the near- and long-term morbidities that can occur after, and persis
Autor:
Natasha S. Crowcroft, Lisa Strifler, Jeffrey C. Kwong, Frances B. Jamieson, Shaun K. Morris, Peter C. Coyte, Shelley L. Deeks, Beate Sander, Hong Anh T. Tu, Murray Krahn
Publikováno v:
Vaccine. 32(42)
Objective Invasive Neisseria meningitidis serogroup B (MenB) disease is a low incidence but severe infection (mean annual incidence 0.19/100,000/year, case fatality 11%, major long-term sequelae 10%) in Ontario, Canada. This study assesses the cost-e
Publikováno v:
Expert review of vaccines, 12(12), 1479-1494. TAYLOR & FRANCIS LTD
Economic evaluations of hepatitis A vaccination are important to assist national and international policy makers in different jurisdictions on making effective decisions. Up to now, a comprehensive review of the potential health and economic benefits
Autor:
Shu-Chuen Li, Herman J. Woerdenbag, Maarten J. Postma, Mark H. Rozenbaum, Peter C. Coyte, Hong-Anh T Tu
Publikováno v:
Vaccine, 30(8), 1521-1528. ELSEVIER SCI LTD
Introduction: Rotavirus is the most common cause of severe diarrhoea worldwide. Vietnam is situated in the region of high rotavirus infection incidence and eligible for financial support to introduce rotavirus vaccines into the Expanded Program of Im
Autor:
Herman J. Woerdenbag, Shu-Chuen Li, Maarten J. Postma, Mark H. Rozenbaum, Hong-Anh T Tu, Sumit Kane
Publikováno v:
Expert review of vaccines, 10(7), 1037-1051. TAYLOR & FRANCIS LTD
Diarrhea is a leading cause of mortality for children under 5 years of age, and rotavirus is identified as the main cause of severe diarrhea worldwide. Since 2006, two rotavirus vaccines, Rotarix and Rotateq, have been available in the market. These